BCL10 monoclonal antibody

Bcl10, also designated CIPER, c-CARMEN and mE10, was first identified as a gene truncated or mutated in MALT B cell lymphomas and other tumor types.Bcl10 is homologous to the equine herpes virus-2 E10 gene, and like E10 it contains an amino-terminal caspase recruitment domain (CARD) . Expression of Bcl10 was shown to induce NFκB activation in a NIK-dependent pathway, and the CARD domain was shown to be essential for this activation. In a separate study, Bcl10 by itself did not induce JNK or NFκB activation. Overexpression of Bcl10 was shown to induce apoptosis, in a manner that was dependent on CARD-mediated oligomerization. Bcl10 was also shown to play a role in processing of caspase-9 to its active dimer. Other studies have shown that Bcl10 is not mutated in many human tumors and lymphomas.

CIPER; CLAP; B-cell lymphoma/leukemia 10; B-cell CLL/lymphoma 10; Bcl-10; CARD-containing molecule enhancing NF-kappa-B; CARD-like apoptotic protein; hCLAP; CED-3/ICH-1 prodomain homologous E10-like regulator; CIPER; Cellular homolog of vCARMEN; cCARMEN; Cellular-E10; c-E10; Mammalian CARD-containing adapter molecule E10; mE10